PYPD
PolyPid Ltd.
NASDAQ:PYPD
$77.9M MC · 10.2M shares · 75 employees

PolyPid Ltd. PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Content on this page require a membership to view — $9/mo.

News

This data requires membership

Sales

This data requires membership

SEC filing

This data requires membership

Catalysts

This data requires membership

Drug pipelines

This data requires membership

Foreign approvals

This data requires membership

Insider trades

This data requires membership

Device pipelines

This data requires membership

Analyst ratings

This data requires membership
biotech.bet © 2026